ID BIONi010-C-NKX2.5-T2A-Nluc-44.37 AC CVCL_C0VT SY #44.37 DR Wikidata; Q114310752 RX PubMed=33660062; CC Population: African. CC Biotechnology: Part of the PluriLum assay which is used for predicting developmental toxicity which relies on the formation of embryoid bodies (EBs) and the differentiation of these into cardiomyocytes (PubMed=33660062). CC Characteristics: Using CRISPR/Cas9 a T2A-Nluc construct was inserted at the C-terminus of both alleles of NKX2-5 (PubMed=33660062). CC Genetic integration: Method=CRISPR/Cas9; Gene=Oplophorus gracilirostris NanoLuc (Note=19 kDa ATP-independent bright luminescent protein derived from O.gracilirostris luciferase). CC Derived from site: In situ; Skin, dermis; UBERON=UBERON_0002067. CC Cell type: Fibroblast of skin; CL=CL_0002620. OX NCBI_TaxID=9606; ! Homo sapiens (Human) HI CVCL_1E68 ! BIONi010-C SX Male AG 18Y CA Induced pluripotent stem cell DT Created: 22-09-22; Last updated: 14-08-25; Version: 6 // RX PubMed=33660062; DOI=10.1007/s00204-021-03018-y; PMCID=PMC8113199; RA Lauschke, Karin RA Treschow, Andreas Frederik RA Rasmussen, Mikkel Aabech RA Davidsen, Nichlas RA Holst, Bjorn RA Emneus, Jenny RA Taxvig, Camilla RA Vinggaard, Anne Marie RT "Creating a human-induced pluripotent stem cell-based NKX2.5 reporter RT gene assay for developmental toxicity testing."; RL Arch. Toxicol. 95:1659-1670(2021). //